4.5 Article

Cardiomyocyte-targeted overexpression of the coxsackie-adenovirus receptor causes a cardiomyopathy in association with β-catenin signaling

Journal

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Volume 48, Issue 6, Pages 1194-1205

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.yjmcc.2010.01.022

Keywords

Cardiomyopathy; Coxsackie-adenovirus receptor; Beta-catenin; Cadherin; Akt

Funding

  1. Heart and Stroke Foundation of Ontario [T6136]

Ask authors/readers for more resources

The coxsackie-adenovirus receptor (CAR) is an adhesion molecule found at the intercalated disc of cardiomyocytes in association with other adherens and tight junction proteins. CAR expression is increased at cardiomyocyte junctions in patients with heart failure. It is not known what contribution elevated CAR expression makes to cardiac pathology. We generated a binary transgenic mouse enabling cardiac-restricted doxycycline-regulated expression of Flag-tagged murine CAR (mCAR(+)/alpha MtTA(+) mice). Myocardial CAR levels were increased 6-fold in mCAR(+)/alpha MtTA(+) mice, localizing to intercalated discs and sarcolemma. Well at birth, mCAR(+)/alpha MtTA(+) mice developed a severe cardiomyopathy and died by 4 weeks. Cardiomyocyte hypertrophy was evident at 1 week, with increased heart:body weight ratios by 3 weeks. Disorganization and degeneration of cardiomyocytes were evident with disrupted adherens junctions. Doxycycline administration turned off transgene expression and rescued mice from the development of the cardiomyopathic phenotype. In CAR-overexpressing mCAR(+)/alpha MtTA(+) mice, adherens junction proteins were abnormally expressed. N-cadherin protein levels were 83% lower in mCAR(+)/alpha MtTA(+) hearts vs controls at 1 week, with levels subsequently increased above controls at 3 weeks. beta-catenin expression was 90% and 135% above controls at 1 and 3 weeks, respectively. Nuclear translocation of beta-catenin in cardiomyocytes of mCAR(+)/alpha MtTA(+) mice was associated with increased c-myc RNA, a target of active beta-catenin known to be associated with cardiac hypertrophy. Our study is the first to demonstrate that increased CAR expression can induce a cardiomyopathy and supports a model whereby the pathogenesis is determined by CAR stimulated beta-catenin signaling, and/or disruption of the adherens junction. (C) 2010 Elsevier Ltd. All rights reserved,

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Medicine, General & Internal

Incidental COVID-19 on PET/CT imaging

Reshma Amin, Leonard Grinblat, Mansoor Husain

CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)

Article Cardiac & Cardiovascular Systems

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure

Steven P. Marso, Florian M. M. Baeres, Stephen C. Bain, Bryan Goldman, Mansoor Husain, Michael A. Nauck, Neil R. Poulter, Richard E. Pratley, Anne Bloch Thomsen, John B. Buse

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Article Biology

Functional culture and in vitro genetic and small-molecule manipulation of adult mouse cardiomyocytes

Neal Callaghan, Shin-Haw Lee, Sina Hadipour-Lakmehsari, Xavier A. Lee, M. Ahsan Siraj, Amine Driouchi, Christopher M. Yip, Mansoor Husain, Craig A. Simmons, Anthony O. Gramolini

COMMUNICATIONS BIOLOGY (2020)

Article Endocrinology & Metabolism

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide

Subodh Verma, Udi Fainberg, Mansoor Husain, Soren Rasmussen, Lars Ryden, Maria Sejersten Ripa, John B. Buse

Summary: After re-categorization, semaglutide significantly reduced the risk of MACE in the established CVD subgroup, while showing a nonsignificant reduction in the CV risk factor subgroup. These results suggest potential CV benefits of semaglutide across the CV risk continuum in patients with type 2 diabetes.

DIABETES OBESITY & METABOLISM (2021)

Article Endocrinology & Metabolism

Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial

Michael E. Nassif, Sheryl L. Windsor, Fengming Tang, Mansoor Husain, Silvio E. Inzucchi, Darren K. McGuire, Bertram Pitt, Benjamin M. Scirica, Bethany Austin, Michael W. Fong, Shane J. LaRue, Guillermo Umpierrez, Justin Hartupee, Yevgeniy Khariton, Ali O. Malik, Modele O. Ogunniyi, Nanette K. Wenger, Mikhail N. Kosiborod

Summary: This study found that using dapagliflozin can lead to improvement in lung fluid volume in patients with HF, as measured by remote dielectric sensing. This discovery provides a clue to unraveling the mechanisms of benefit of SGLT2 inhibitors in heart failure.

DIABETES OBESITY & METABOLISM (2021)

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Patrick R. Lawler, Ewan C. Golighe, Jeffrey S. Berge, Matthew D. Neal, Bryan J. McVerry, Jose C. Nicolau, Michelle N. Gong, Marc Carrier, Robert S. Rosenson, Harmony R. Reynolds, Alexis F. Turgeon, Jorge Escobedo, David T. Huang, Charlotte A. Bradbury, Brett L. Houston, Lucy Z. Kornblith, Anand Kumar, Susan R. n Kah, Mary Cushman, Zoe McQuilten, Arthur S. Slutsky, Keri S. Kim, Anthony C. Gordon, Bridget-Anne Kirwan, Maria M. Brooks, Alisa M. Higgins, Roger J. Lewis, Elizabeth Lorenzi, Scott M. Berry, Lindsay R. Berry, Derek C. Angus, Colin J. McArthur, Steven A. Webb, Michael E. Farkouh, Judith S. Hochman, Ryan Zarychanski, Aaron W. Aday, Farah Al-Beidh, Djillali Annane, Yaseen M. Arabi, Diptesh Aryal, Lisa Baumann Kreuziger, Abi Beane, Zahra Bhimani, Shailesh Bihari, Henny H. Billett, Lindsay Bond, Marc Bonten, Frank Brunkhorst, Meredith Buxton, Adrian Buzgau, Lana A. Castellucci, Sweta Chekuri, Jen-Ting Chen, Allen C. Cheng, Tamta Chkhikvadzw, Benjamin Coiffard, Todd W. Costantini, Sophie de Brouwer, Lennie P. G. Derde, Michelle A. Detry, Abhijit Duggal, Vladimir Dzavik, Mark B. Effron, Lise J. Estcourt, Brendan M. Everett, Dean A. Fergusson, Mark Fitzgerald, Robert A. Fowler, Jean P. Galanaud, Benjamin T. Galen, Sheetal Gandotra, Sebastian Garcia-Madrona, Timothy D. Girard, Lucas C. Godoy, Andrew L. Goodman, Herman Goossens, Cameron Green, Yonatan Y. Greenstein, Peter L. Gross, Naomi M. Hamburg, Rashan Haniffa, George Hanna, Nicholas Hanna, Sheila M. Hegde, Carolyn M. Hendrickson, R. Duncan Hite, Alexander A. Hindenburg, Aluko A. Hope, James M. Horowitz, Christopher M. Horvat, Kristin Hudock, Beverley J. Hunt, Mansoor Husain, Robert C. Hyzy, Vivek N. Iyer, Jeffrey R. Jacobson, Devachandran Jayakumar, Norma M. Keller, Akram Khan, Yuri Kim, Andrei L. Kindzelski, Andrew J. Kin, M. Margaret Knudson, Aaron E. Kornblith, Vidya Krishnan, Matthew E. Kutcher, Michael A. Laffan, Francois Lamontagne, Gregoire Le Gal, Christine M. Leeper, Eric S. Leifer, George Lim, Felipe Gallego Lima, Kelsey Linstrum, Edward Litton, Jose Lopez-Sendon, Jose L. Lopez-Sendon Moreno, Sylvain A. Lother, Saurabh Malhotra, Miguel Marcos, Andrea Saud Marinez, John C. Marshall, Nicole Marten, Michael A. Matthay, Daniel F. McAuley, Emily G. McDonald, Anna McGlothlin, Shay P. McGuinness, Saskia Middeldorp, Stephanie K. Montgomery, Steven C. Moore, Raquel Morillo Guerreor, Paul R. Mouncey, Srinivas Murthy, Girish B. Nair, Rahul Nair, Alistair D. Nichol, Brenda Nunez-Garcia, Ambarish Pandey, Pauline K. Park, Rachael L. Parke, Jane C. Parker, Sam Parnia, Jonathan D. Paul, Yessica S. Perez Gonzalez, Mauricio Pompilio, Matthew E. Prekker, John G. Quigley, Natalia S. Rost, Kathryn Rowan, Fernanda O. Santos, Marlene Santos, Mayler Olombrada Santos, Lewis Satterwhite, Christina T. Saunders, Roger E. G. Schutgens, Christopher W. Seymour, Deborah M. Siegal, Delcio G. Silva, Manu Shankar-Hari, John P. Sheehan, Aneesh B. Singhal, Dayna Solvaso, Simon J. Stanworth, Tobias Tritschler, Anne M. Turner, Wilma Van Bentum-Puijk, Frank L. van de Veerdonk, Sean van Diepen, Gloria Vazquez-Grande, Lana Wahid, Vanessa Wareham, Bryan J. Wells, R. Jay Widmer, Jennifer G. Wilson, Eugene Yuriditsky, Fernando G. Zampieri

Summary: This study showed that therapeutic-dose anticoagulation with heparin in non-critically ill patients with Covid-19 increased the likelihood of survival to hospital discharge and reduced the need for cardiovascular or respiratory organ support compared to usual-care thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Ewan C. Goligher, Charlotte A. Bradbury, Bryan J. McVerry, Patrick R. Lawler, Jeffrey S. Berger, Michelle N. Gong, Marc Carrier, Harmony R. Reynolds, Anand Kumar, Alexis F. Turgeon, Lucy Z. Kornblith, Susan R. Kahn, John C. Marshall, Keri S. Kim, Brett L. Houston, Lennie P. G. Derde, Mary Cushman, Tobias Tritschler, Derek C. Angus, Lucas C. Godoy, Zoe McQuilten, Bridget-Anne Kirwan, Michael E. Farkouh, Maria M. Brooks, Roger J. Lewis, Lindsay R. Berry, Elizabeth Lorenzi, Anthony C. Gordon, Scott M. Berry, Colin J. McArthur, Matthew D. Neal, Judith S. Hochman, Steven A. Webb, Ryan Zarychanski, Tania Ahuja, Farah Al-Beidh, Djillali Annane, Yaseen M. Arabi, Diptesh Aryal, Lisa Baumann Kreuziger, Abi Beane, Zahra Bhimani, Shailesh Bihari, Henny H. Billett, Lindsay Bond, Marc Bonten, Frank Brunkhorst, Meredith Buxton, Adrian Buzgau, Lana A. Castellucci, Sweta Chekuri, Jen-Ting Chen, Allen C. Cheng, Tamta Chkhikvadze, Benjamin Coiffard, Aira Contreras, Todd W. Costantini, Sophie de Brouwer, Michelle A. Detry, Abhijit Duggal, Vladimir Dzavik, Mark B. Effron, Heather F. Eng, Jorge Escobedo, Lise J. Estcourt, Brendan M. Everett, Dean A. Fergusson, Mark Fitzgerald, Robert A. Fowler, Joshua D. Froess, Zhuxuan Fu, Jean P. Galanaud, Benjamin T. Galen, Sheetal Gandotra, Timothy D. Girard, Andrew L. Goodman, Herman Goossens, Cameron Green, Yonatan Y. Greenstein, Peter L. Gross, Rashan Haniffa, Sheila M. Hegde, Carolyn M. Hendrickson, Alisa M. Higgins, Alexander A. Hindenburg, Aluko A. Hope, James M. Horowitz, Christopher M. Horvat, David T. Huang, Kristin Hudock, Beverley J. Hunt, Mansoor Husain, Robert C. Hyzy, Jeffrey R. Jacobson, Devachandran Jayakumar, Norma M. Keller, Akram Khan, Yuri Kim, Andrei Kindzelski, Andrew J. King, Aaron E. Kornblith, Matthew E. Kutcher, Michael A. Laffan, Francois Lamontagne, Gregoire Le Gal, Christine M. Leeper, Eric S. Leifer, George Lim, Felipe Gallego Lima, Kelsey Linstrum, Edward Litton, Jose Lopez-Sendon, Sylvain A. Lother, Nicole Marten, Andrea Saud Marinez, Mary Martinez, Eduardo Mateos Garcia, Stavroula Mavromichalis, Daniel F. McAuley, Emily G. McDonald, Anna McGlothlin, Shay P. McGuinness, Saskia Middeldorp, Stephanie K. Montgomery, Paul R. Mouncey, Srinivas Murthy, Girish B. Nair, Rahul Nair, Alistair D. Nichol, Jose C. Nicolau, Brenda Nunez-Garcia, John J. Park, Pauline K. Park, Rachael L. Parke, Jane C. Parker, Sam Parnia, Jonathan D. Paul, Mauricio Pompilio, John G. Quigley, Robert S. Rosenson, Natalia S. Rost, Kathryn Rowan, Fernanda O. Santos, Marlene Santos, Mayler O. Santos, Lewis Satterwhite, Christina T. Saunders, Jake Schreiber, Roger E. G. Schutgens, Christopher W. Seymour, Deborah M. Siegal, Delcio G. Silva, Aneesh B. Singhal, Arthur S. Slutsky, Dayna Solvason, Anne M. Turner, Wilma Van Bentum-Puijk, Frank L. van de Veerdonk, Sean van Diepen, Gloria Vazquez-Grande, Lana Wahid, Vanessa Wareham, R. Jay Widmer, Jennifer G. Wilson, Eugene Yuriditsky, Yongqi Zhong

Summary: In critically ill patients with Covid-19, initial therapeutic-dose anticoagulation did not result in improved survival rates or fewer days requiring cardiovascular or respiratory organ support compared to usual-care pharmacologic thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Cardiac & Cardiovascular Systems

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

Senthil Selvaraj, Zhuxuan Fu, Philip Jones, Lydia C. Kwee, Sheryl L. Windsor, Olga Ilkayeva, Christopher B. Newgard, Kenneth B. Margulies, Mansoor Husain, Silvio E. Inzucchi, Darren K. McGuire, Bertram Pitt, Benjamin M. Scirica, David E. Lanfear, Michael E. Nassif, Ali Javaheri, Robert J. Mentz, Mikhail N. Kosiborod, Svati H. Shah

Summary: This study explored the effects of dapagliflozin on metabolic pathways in HFrEF patients, showing an increase in ketone-related and fatty acid metabolite clusters. It also identified metabolic biomarkers associated with adverse HFrEF outcomes, suggesting a potential role for altered ketone and fatty acid biology with sodium-glucose cotransporter-2 inhibitors.

CIRCULATION (2022)

Article Clinical Neurology

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6

W. David Strain, Ofir Frenkel, Martin A. James, Lawrence A. Leiter, Soren Rasmussen, Peter M. Rothwell, Maria Sejersten Ripa, Thomas C. Truelsen, Mansoor Husain

Summary: This post hoc analysis found that GLP-1 RA drug semaglutide can reduce stroke risk in patients with type 2 diabetes, especially the risk of small-vessel occlusion, compared to placebo.

STROKE (2022)

Review Cardiac & Cardiovascular Systems

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes

Nikolaus Marx, Mansoor Husain, Michael Lehrke, Subodh Verma, Naveed Sattar

Summary: Multiple large cardiovascular outcome trials have shown that SGLT2 inhibitors and GLP-1 receptor agonists significantly reduce cardiovascular disease risk in patients with type 2 diabetes, including major adverse cardiovascular events and heart failure. These drugs have received strong recommendations in diabetes and cardiology guidelines, but their usage remains low.

CIRCULATION (2022)

Article Endocrinology & Metabolism

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes

Vanita R. R. Aroda, Umut Erhan, Peter Jelnes, Juris J. J. Meier, Morten Tind Abildlund, Richard Pratley, Tina Vilsboll, Mansoor Husain

Summary: Glucagon-like peptide-1 receptor agonists, including oral and subcutaneous semaglutide, are effective in improving glycaemic control and reducing cardiovascular risk. This study analyzed adverse events from clinical trials and found that the most common side effects were gastrointestinal disorders, which decreased with continued therapy.

DIABETES OBESITY & METABOLISM (2023)

Article Cardiac & Cardiovascular Systems

Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials

Kashvi Gupta, John A. Spertus, Mary Birmingham, Kensey L. Gosch, Mansoor Husain, Dalane W. Kitzman, Bertram Pitt, Sanjiv J. Shah, James L. Januzzi, Ildiko Lingvay, Javed Butler, Mikhail Kosiborod, David E. Lanfear

Summary: The health status of Black patients with heart failure is worse compared to White patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) can reduce cardiovascular mortality and improve health status in heart failure patients, but it is unclear if the effect is similar across races. The study found that SGLT2i improves health status equally for Black and White patients.

CIRCULATION (2023)

Article Cardiac & Cardiovascular Systems

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials

Michael E. Nassif, Sheryl L. Windsor, Kensey Gosch, Barry A. Borlaug, Mansoor Husain, Silvio E. Inzucchi, Dalane W. Kitzman, Darren K. McGuire, Bertram Pitt, Benjamin M. Scirica, Sanjiv J. Shah, Guillermo Umpierrez, Bethany A. Austin, Sumant Lamba, Taiyeb Khumri, Kavita Sharma, Mikhail N. Kosiborod

Summary: The benefits of SGLT2 inhibitors on symptoms and physical limitations in patients with heart failure are consistent and clinically meaningful across the full range of ejection fraction (EF), according to a pooled analysis of two trials.

CIRCULATION-HEART FAILURE (2023)

Letter Endocrinology & Metabolism

Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials

Subodh Verma, Mansoor Husain, Christian M. Madsen, Lawrence A. Leiter, Anja Birk Kuhlman, Tina Vilsboll, Soren Rasmussen, Peter Libby

DIABETES OBESITY & METABOLISM (2023)

Article Endocrinology & Metabolism

Roles of vascular endothelial and smooth muscle cells in the vasculoprotective effect of insulin in a mouse model of restenosis

Yusaku Mori, Marel Gonzalez Medina, Zhiwei Liu, June Guo, Luke S. Dingwell, Simon Chiang, Carl Ronald Kahn, Mansoor Husain, Adria Giacca

Summary: The study found that the vasculoprotective effects of insulin on inhibiting neointimal growth require action in both endothelial cells and vascular smooth muscle cells.

DIABETES & VASCULAR DISEASE RESEARCH (2021)

Article Cardiac & Cardiovascular Systems

Epicardial deletion of Sox9 leads to myxomatous valve degeneration and identifies Cd109 as a novel gene associated with valve development

Andrew B. Harvey, Renelyn A. Woltes, Raymond N. Deepe, Hannah G. Tarolli, Jenna R. Drummond, Allison Trouten, Auva Zandi, Jeremy L. Barth, Rupak Mukherjee, Martin J. Romeo, Silvia G. Vaena, Ge Tao, Robin Muise-Helmericks, Paula S. Ramos, Russell A. Norris, Andy Wessels

Summary: This study highlights the importance of SOX9 in the regulation of epicardial cell invasion and emphasizes the role of EPDCs in regulating atrioventricular valve development and homeostasis. It also reports a novel expression profile of Cd109, a gene with previously unknown relevance in heart development.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2024)

Review Cardiac & Cardiovascular Systems

Mechanistic target of rapamycin in regulating macrophage function in inflammatory cardiovascular diseases

MariaSanta C. Mangione, Jinhua Wen, Dian J. Cao

Summary: mTOR, a mechanistic target of rapamycin, is an evolutionarily conserved pathway that plays a fundamental role in nutrient sensing, growth, metabolism, lifespan, and aging. Recent studies have highlighted the regulatory role of mTOR in innate immune responses and its involvement in the pathogenesis of cardiovascular diseases, especially in acute inflammation and atherosclerotic cardiovascular disease. This review also discusses mTOR's role in trained immunity, immune senescence, and clonal hematopoiesis, as well as its architecture and regulatory complexes.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2024)

Article Cardiac & Cardiovascular Systems

Classification of regulatory T cells and their role in myocardial ischemia-reperfusion injury

Junlin Li, Yajun Gong, Yiren Wang, Huihui Huang, Huan Du, Lianying Cheng, Cui Ma, Yongxiang Cai, Hukui Han, Jianhong Tao, Gang Li, Panke Cheng

Summary: Myocardial ischemia-reperfusion injury is closely related to the final infarct size in acute myocardial infarction. Regulatory T cells play an important role in the inflammatory response after AMI, but different subtypes of Tregs have different effects on the injury.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2024)

Article Cardiac & Cardiovascular Systems

β-hydroxybutyrate administered at reperfusion reduces infarct size and preserves cardiac function by improving mitochondrial function through autophagy in male mice

Yuxin Chu, Yutao Hua, Lihao He, Jin He, Yunxi Chen, Jing Yang, Ismail Mahmoud, Fanfang Zeng, Xiaochang Zeng, Gloria A. Benavides, Victor M. Darley-Usmar, Martin E. Young, Scott W. Ballinger, Sumanth D. Prabhu, Cheng Zhang, Min Xie

Summary: This study demonstrates that administering beta-hydroxybutyrate (beta-OHB) at the time of reperfusion can reduce infarct size and preserve cardiac function by activating autophagy and preserving mitochondrial homeostasis, potentially through mTOR inhibition.

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2024)